Abstract
Background/objectives: Debilitating abdominal pain is a common symptom affecting patients with chronic pancreatitis (CP). CP pain is dynamic due to multiple underlying mechanisms. The objective of this study was to 1) evaluate changes in pain phenotype at one year follow-up and 2) validate putative pain biomarkers in a prospective cohort study. Methods: The Neuropathic and Nociceptive PROMIS-PQ questionnaires were used to classify pain for participants with in the PROCEED study. Putative serum biomarkers were measured via immunoassay. Results: At enrollment, 17.6 % (120/681) subjects with CP reported no pain in the previous year. Of those, 29 % experienced pain during the 1 yr follow-up whereas 18 % of those with pain prior to enrollment reported no pain during the 1 yr follow-up period. Of the 393 subjects with PROMIS-PQ data at enrollment, 212 also had follow-up data at 1 yr. Approximately half (53.3 %) of those individuals changed pain phenotype between baseline and follow-up. At 1 yr, serum TGFβ1 level was negatively correlated with nociceptive T-scores (p = 0.006). GP130 was significantly correlated with both nociceptive (p = 0.012) and neuropathic T-scores (p = 0.043) at 1 yr, which is consistent with the previously published findings. Conclusions: The positive association between TGFβ1 and pain is not maintained over time, suggesting it is a poor pain biomarker. However, serum GP130 is a consistent biomarker for mixed-type pain in CP. Preclinical studies show that targeting TGFβ1 or IL-6 (ligand for GP130) is sufficient to inhibit CP pain supporting further investigation of this as a potential therapeutic target.
| Original language | English |
|---|---|
| Pages (from-to) | 993-1002 |
| Number of pages | 10 |
| Journal | Pancreatology |
| Volume | 24 |
| Issue number | 7 |
| DOIs | |
| State | Published - Nov 2024 |
Bibliographical note
Publisher Copyright:© 2024 IAP and EPC
Funding
PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies (PROCEED) is funded through the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) which is sponsored by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases. PROCEED is a prospective observational study of US adult subjects across the pancreatitis spectrum (ranging from no pancreas disease to acute to CP) [24]. Subjects were enrolled at 9 participating clinical centers: University of Pittsburgh Medical Center, Indiana University School of Medicine, Mayo Clinic, Baylor College of Medicine, University of Florida, The Ohio State University Wexner Medical Center, Cedars-Sinai Medical Center, Stanford University School of Medicine, and Kaiser Permanente.This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): R21DK122293 and K01DK120737 (JLS). The National Cancer Institute (NCI) and NIDDK for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) under award numbers: U01DK108288(Mayo Clinic), U01DK108300 (Stanford), U01DK108306(University of Pittsburgh Medical Center), U01DK108314(Cedars-Sinai Medical Center), U01DK108323(Indiana University), U01DK108326(Baylor College of Medicine), U01DK108327(The Ohio State University), U01DK108332(Kaiser Permanente), U01DK108320(University of Florida) and U01DK108328(MD Anderson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): R21DK122293 and K01DK120737 (JLS). The National Cancer Institute (NCI) and NIDDK for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) under award numbers: U01DK108288 (Mayo Clinic), U01DK108300 (Stanford), U01DK108306 (University of Pittsburgh Medical Center), U01DK108314 (Cedars-Sinai Medical Center), U01DK108323 (Indiana University), U01DK108326 (Baylor College of Medicine), U01DK108327 (The Ohio State University), U01DK108332 (Kaiser Permanente), U01DK108320 (University of Florida) and U01DK108328 (MD Anderson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
| Funders | Funder number |
|---|---|
| Mayo Clinic Rochester | |
| Pancreatic Cancer Canada Foundation | |
| University of Florida College of Medicine | |
| Indiana University School of Medicine | |
| Ohio State University Wexner Medical Center | |
| Cedars-Sinai Medical Center | |
| National Institutes of Health (NIH) | |
| National Childhood Cancer Registry – National Cancer Institute | |
| University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh | |
| National Institute of Diabetes and Digestive and Kidney Diseases | R21DK122293, K01DK120737 |
| National Institute of Diabetes and Digestive and Kidney Diseases | |
| Stanford Cardiovascular Institute, School of Medicine, Stanford University | R21DK122293, K01DK120737 |
| Stanford Cardiovascular Institute, School of Medicine, Stanford University | |
| Florida AandM University and Florida State University | U01DK108328 |
| Florida AandM University and Florida State University | |
| CPDPC | U01DK108306, U01DK108323, U01DK108314, U01DK108300, U01DK108288 |
| Baylor College of Medicine | U01DK108327 |
| Baylor College of Medicine | |
| Ohio Water Resources Center, Ohio State University | U01DK108320, U01DK108332 |
| Ohio Water Resources Center, Ohio State University | |
| University of Southern Indiana | U01DK108326 |
| University of Southern Indiana |
Keywords
- Chronic pancreatitis
- GP130
- PROMIS-PQ
- Pain
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology
